Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 15/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.54 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.54 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390914 | 0.91 | MAP2K1 (0.54) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL391030 | 0.90 | MAP2K1 (0.54) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL391190 | 0.88 | MAP2K1 (0.49) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL345633 | 0.88 | MAP2K1 (0.71) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL11909650 | 0.88 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL11909830 | 0.88 | MAP2K1 (0.58) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL19050661 | 0.88 | MAP2K2 (0.44) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL392701 | 0.85 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL392045 | 0.85 | MAP2K1 (0.59) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1979211 | 0.83 | MAP2K1 (0.45) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES (US) | 2014-12-25 | — | — | US | disclosed |
| US-8829052-B2 | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8808742-B2 | Compositions and methods for preparing and using same | ARDEA BIOSCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8648116-B2 | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | ARDEA BIOSCIENCES, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120136030-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120022076-A1 | DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK | MADERNA ANDREAS (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2291350-A2 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | Ardea Biosciences, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | ARDEA BIOSCIENCES, INC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | ARDEA BIOSCIENCES, INC (US) | 2011-02-10 | — | — | US | disclosed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022076-A1 | DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAP2K1 52/4885MAP2K2 48/4885CHEK1 260/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAP2K1 52/4885MAP2K2 48/4885CHEK1 260/4885 |
| US-20120136030-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | MAP2K1 71/4885MAP2K2 74/4885CHEK1 164/4885 |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | MAP2K1 71/4885MAP2K2 74/4885CHEK1 164/4885 |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAP2K1 52/4885MAP2K2 48/4885CHEK1 260/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | MAP2K1 7/4885MAP2K2 3/4885CHEK1 507/4885 |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | NRAS, BRAF, MAP3K2 | MAP2K1 28/4885MAP2K2 21/4885CHEK1 125/4885 |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | HMGCR, PCSK9, C5 | MAP2K1 4649/4885MAP2K2 4647/4885CHEK1 3093/4885 |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | NRAS, KRAS, TP53 | MAP2K1 110/4885MAP2K2 116/4885CHEK1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.